Federal policy relating to providing federal funding to strengthen capabilities for domestic manufacturing of generic drugs and their ingredients; and Federal policy relating to amending Hatch-Waxman Act 180-day exclusivity eligibility to provide incentives for manufacturing generic pharmaceuticals and their ingredients in the United States and allied nations.
Source-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- Not reported
- Expenses
- $730,000.00
- Registrant
- APOTEX CORP.
- Client
- APOTEX CORP.
- Filing UUID
- 7a964508-e847-411a-9959-4ea41bbf3fc7
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Federal policy relating to the review of the United States-Mexico-Canada trade agreement and the North American generic drug supply chain.
HR 6485/S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; Federal policy relating to the Patent and Trademark Offices Revisions to Rules of Practice before the Patent Trial and Appeal Board notice of proposed rulemaking [Docket No. PTO-P-2025-0025] requiring Inter Partes Review (IPR) filers to choose between district court litigation and IPR; and Federal policy relating to Patent and Trademark Office discretionary denials of IPR institution.
HR 5526/S. 1954, the Biosimilar Red Tape Elimination Act, provisions relating to deeming a biosimilar interchangeable with its reference product immediately upon approval.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.